Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567299529> ?p ?o ?g. }
- W2567299529 endingPage "385" @default.
- W2567299529 startingPage "380" @default.
- W2567299529 abstract "BackgroundAngiogenesis is implicated in formation of gastrointestinal arteriovenous malformations (AVMs). Angiotensin II signaling is involved in angiogenesis through the vascular endothelial growth factor (VEGF) and angiopoietin-2 pathways. We hypothesized that angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy would be associated with a reduced risk of all-cause gastrointestinal bleeding (GIB) and AVM-associated GIB in patients with left ventricular assist devices (LVADs).MethodsWe reviewed records of all adult patients receiving a continuous-flow LVAD (HeartMate II or HeartWare HVAD) at Johns Hopkins Hospital between January 2004 and December 2014. Of 192 patients, 131 were included for final analyses. Logistic regression analysis adjusting for demographic, cardiovascular, and laboratory variables was used to assess the association of ACEI or ARB therapy with GIB.ResultsOf 131 patients, 100 received ACEI or ARB therapy during LVAD support. Of the 31 patients who did not receive ACEI or ARB, 15 experienced GIB (48%), with 9 caused by AVMs (29%). Of 100 patients who received ACEI or ARB therapy, 24 experienced GIB (24%), with 9 caused by AVMs (9%). Logistic regression hazards model demonstrated that ACEI or ARB therapy was independently associated with a reduced risk for all-cause GIB (odds ratio 0.29, 95% confidence interval 0.12–0.72) and AVM-related GIB (odds ratio 0.23, 95% confidence interval 0.07–0.71).ConclusionsAngiotensin II antagonism is associated with a reduced risk of AVM-related GIB in patients with LVADs. This association is independent of age, sex, blood pressure, renal function, international normalized ratio, LVAD type, and cardiomyopathy etiology. Angiogenesis is implicated in formation of gastrointestinal arteriovenous malformations (AVMs). Angiotensin II signaling is involved in angiogenesis through the vascular endothelial growth factor (VEGF) and angiopoietin-2 pathways. We hypothesized that angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy would be associated with a reduced risk of all-cause gastrointestinal bleeding (GIB) and AVM-associated GIB in patients with left ventricular assist devices (LVADs). We reviewed records of all adult patients receiving a continuous-flow LVAD (HeartMate II or HeartWare HVAD) at Johns Hopkins Hospital between January 2004 and December 2014. Of 192 patients, 131 were included for final analyses. Logistic regression analysis adjusting for demographic, cardiovascular, and laboratory variables was used to assess the association of ACEI or ARB therapy with GIB. Of 131 patients, 100 received ACEI or ARB therapy during LVAD support. Of the 31 patients who did not receive ACEI or ARB, 15 experienced GIB (48%), with 9 caused by AVMs (29%). Of 100 patients who received ACEI or ARB therapy, 24 experienced GIB (24%), with 9 caused by AVMs (9%). Logistic regression hazards model demonstrated that ACEI or ARB therapy was independently associated with a reduced risk for all-cause GIB (odds ratio 0.29, 95% confidence interval 0.12–0.72) and AVM-related GIB (odds ratio 0.23, 95% confidence interval 0.07–0.71). Angiotensin II antagonism is associated with a reduced risk of AVM-related GIB in patients with LVADs. This association is independent of age, sex, blood pressure, renal function, international normalized ratio, LVAD type, and cardiomyopathy etiology." @default.
- W2567299529 created "2017-01-06" @default.
- W2567299529 creator A5004253282 @default.
- W2567299529 creator A5005072323 @default.
- W2567299529 creator A5007247112 @default.
- W2567299529 creator A5016637019 @default.
- W2567299529 creator A5030914772 @default.
- W2567299529 creator A5037292220 @default.
- W2567299529 creator A5049772348 @default.
- W2567299529 creator A5050556570 @default.
- W2567299529 creator A5054034179 @default.
- W2567299529 creator A5056479519 @default.
- W2567299529 creator A5073259726 @default.
- W2567299529 creator A5074434599 @default.
- W2567299529 creator A5076454382 @default.
- W2567299529 creator A5078708353 @default.
- W2567299529 date "2017-04-01" @default.
- W2567299529 modified "2023-10-18" @default.
- W2567299529 title "Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices" @default.
- W2567299529 cites W1435000474 @default.
- W2567299529 cites W1950933455 @default.
- W2567299529 cites W1952228674 @default.
- W2567299529 cites W1964249543 @default.
- W2567299529 cites W1970183879 @default.
- W2567299529 cites W1971678928 @default.
- W2567299529 cites W1974499947 @default.
- W2567299529 cites W1984513282 @default.
- W2567299529 cites W1991456443 @default.
- W2567299529 cites W1994126178 @default.
- W2567299529 cites W1995538993 @default.
- W2567299529 cites W1997780004 @default.
- W2567299529 cites W1999098034 @default.
- W2567299529 cites W2006011717 @default.
- W2567299529 cites W2009757771 @default.
- W2567299529 cites W2026070142 @default.
- W2567299529 cites W2028302444 @default.
- W2567299529 cites W2037916260 @default.
- W2567299529 cites W2038831639 @default.
- W2567299529 cites W2055447043 @default.
- W2567299529 cites W2060637042 @default.
- W2567299529 cites W2066690419 @default.
- W2567299529 cites W2077702940 @default.
- W2567299529 cites W2081807748 @default.
- W2567299529 cites W2082169659 @default.
- W2567299529 cites W2082816902 @default.
- W2567299529 cites W2092322834 @default.
- W2567299529 cites W2099940058 @default.
- W2567299529 cites W2118216199 @default.
- W2567299529 cites W2121626542 @default.
- W2567299529 cites W2133830302 @default.
- W2567299529 cites W2145196223 @default.
- W2567299529 cites W2156051913 @default.
- W2567299529 cites W2334854261 @default.
- W2567299529 cites W2497397127 @default.
- W2567299529 cites W2916269539 @default.
- W2567299529 doi "https://doi.org/10.1016/j.healun.2016.12.016" @default.
- W2567299529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28169115" @default.
- W2567299529 hasPublicationYear "2017" @default.
- W2567299529 type Work @default.
- W2567299529 sameAs 2567299529 @default.
- W2567299529 citedByCount "65" @default.
- W2567299529 countsByYear W25672995292017 @default.
- W2567299529 countsByYear W25672995292018 @default.
- W2567299529 countsByYear W25672995292019 @default.
- W2567299529 countsByYear W25672995292020 @default.
- W2567299529 countsByYear W25672995292021 @default.
- W2567299529 countsByYear W25672995292022 @default.
- W2567299529 countsByYear W25672995292023 @default.
- W2567299529 crossrefType "journal-article" @default.
- W2567299529 hasAuthorship W2567299529A5004253282 @default.
- W2567299529 hasAuthorship W2567299529A5005072323 @default.
- W2567299529 hasAuthorship W2567299529A5007247112 @default.
- W2567299529 hasAuthorship W2567299529A5016637019 @default.
- W2567299529 hasAuthorship W2567299529A5030914772 @default.
- W2567299529 hasAuthorship W2567299529A5037292220 @default.
- W2567299529 hasAuthorship W2567299529A5049772348 @default.
- W2567299529 hasAuthorship W2567299529A5050556570 @default.
- W2567299529 hasAuthorship W2567299529A5054034179 @default.
- W2567299529 hasAuthorship W2567299529A5056479519 @default.
- W2567299529 hasAuthorship W2567299529A5073259726 @default.
- W2567299529 hasAuthorship W2567299529A5074434599 @default.
- W2567299529 hasAuthorship W2567299529A5076454382 @default.
- W2567299529 hasAuthorship W2567299529A5078708353 @default.
- W2567299529 hasBestOaLocation W25672995291 @default.
- W2567299529 hasConcept C126322002 @default.
- W2567299529 hasConcept C141071460 @default.
- W2567299529 hasConcept C156957248 @default.
- W2567299529 hasConcept C164705383 @default.
- W2567299529 hasConcept C2778080469 @default.
- W2567299529 hasConcept C2778198053 @default.
- W2567299529 hasConcept C2778774980 @default.
- W2567299529 hasConcept C44249647 @default.
- W2567299529 hasConcept C71924100 @default.
- W2567299529 hasConceptScore W2567299529C126322002 @default.
- W2567299529 hasConceptScore W2567299529C141071460 @default.
- W2567299529 hasConceptScore W2567299529C156957248 @default.
- W2567299529 hasConceptScore W2567299529C164705383 @default.
- W2567299529 hasConceptScore W2567299529C2778080469 @default.